Daratumumab, Cyclophosphamide, Bortezomib, Lenalidomide, and Dexamethasone as Induction and Extended Consolidation Improves Outcome in Ultra-High-Risk Multiple MyelomaMartin Kaiser, Matthew Jenner, Sarah Brown et al.|Journal of Clinical Oncology|2023Cited by 114
Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM studyAntonio Cuneo, Paolo Ghia, George Follows et al.|Haematologica|2018Cited by 35
PI3Kδ and PI3Kγ isoforms have distinct functions in regulating pro-tumoural signalling in the multiple myeloma microenvironmentRachel E. Piddock, Kristian M. Bowles|Blood Cancer Journal|2017Cited by 30
Depth of response and minimal residual disease status in ultra high-risk multiple myeloma and plasma cell leukemia treated with daratumumab, bortezomib, lenalidomide, cyclophosphamide and dexamethasone (Dara-CVRd): Results of the UK optimum/MUKnine trial.Martin Kaiser, Matthew Jenner, Andrew Hall et al.|Journal of Clinical Oncology|2021Cited by 17
Extended Intensified Post-ASCT Consolidation with Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (Dara-VRd) for Ultra-High Risk (UHiR) Newly Diagnosed Myeloma (NDMM) and Primary Plasma Cell Leukemia (pPCL): The UK Optimum/Muknine TrialMartin Kaiser, Matthew Jenner, Andrew Hall et al.|Blood|2022Cited by 10